Okrój M[au] - Search Results

Year	Number of Results
2003	2
2005	1
2006	5
2007	5
2008	5
2009	2
2010	1
2011	1
2012	3
2013	3
2014	2
2015	3
2016	6
2017	3
2018	6
2019	5
2020	4
2021	5
2022	2

1

Editorial: Complement and Immunotherapeutics.

Okrój M, Volokhina E. Okrój M, et al. Front Immunol. 2021 Feb 24;12:663459. doi: 10.3389/fimmu.2021.663459. eCollection 2021. Front Immunol. 2021. PMID: 33717205 Free PMC article. No abstract available.

2

New perspectives on complement mediated immunotherapy.

Stasiłojć G, Österborg A, Blom AM, Okrój M. Stasiłojć G, et al. Among authors: okroj m. Cancer Treat Rev. 2016 Apr;45:68-75. doi: 10.1016/j.ctrv.2016.02.009. Epub 2016 Mar 8. Cancer Treat Rev. 2016. PMID: 26994325 Review.

3

Parameters critical for the effector mechanism of anti-CD20 antibodies revisited.

Stasiłojć G, Felberg A, Okrój M. Stasiłojć G, et al. Among authors: okroj m. Br J Haematol. 2018 Mar;180(6):777-779. doi: 10.1111/bjh.15130. Epub 2018 Feb 7. Br J Haematol. 2018. PMID: 29411875 No abstract available.

4

A tale of the monoclonal anti-CD20 antibodies, in tribute to prof. Wacław Szybalski (1921-2020).

Stasiłojć G, Okrój M, Bigda J. Stasiłojć G, et al. Among authors: okroj m. Acta Biochim Pol. 2021 Aug 31;68(3):353-358. doi: 10.18388/abp.2020_5762. Acta Biochim Pol. 2021. PMID: 34463467 Free article. Review.

5

Rheumatoid arthritis and the complement system.

Okroj M, Heinegård D, Holmdahl R, Blom AM. Okroj M, et al. Ann Med. 2007;39(7):517-30. doi: 10.1080/07853890701477546. Ann Med. 2007. PMID: 17852027 Review.

6

Complement Activation as a Helping Hand for Inflammophilic Pathogens and Cancer.

Okrój M, Potempa J. Okrój M, et al. Front Immunol. 2019 Jan 10;9:3125. doi: 10.3389/fimmu.2018.03125. eCollection 2018. Front Immunol. 2019. PMID: 30687327 Free PMC article. Review.

7

Novel properties of antimicrobial peptides.

Kamysz W, Okrój M, Łukasiak J. Kamysz W, et al. Among authors: okroj m. Acta Biochim Pol. 2003;50(2):461-9. Acta Biochim Pol. 2003. PMID: 12833170 Free article. Review.

8

Regarding: A global anti-B cell strategy combining obinutuzumab and daratumumab in severe pediatric nephrotic syndrome.

Majeranowski A, Okrój M. Majeranowski A, et al. Among authors: okroj m. Pediatr Nephrol. 2021 Jun;36(6):1651-1652. doi: 10.1007/s00467-021-04981-5. Epub 2021 Feb 18. Pediatr Nephrol. 2021. PMID: 33604726 No abstract available.

9

Nephritic Factors: An Overview of Classification, Diagnostic Tools and Clinical Associations.

Corvillo F, Okrój M, Nozal P, Melgosa M, Sánchez-Corral P, López-Trascasa M. Corvillo F, et al. Among authors: okroj m. Front Immunol. 2019 Apr 24;10:886. doi: 10.3389/fimmu.2019.00886. eCollection 2019. Front Immunol. 2019. PMID: 31068950 Free PMC article. Review.

10

Effector mechanisms of anti-CD20 monoclonal antibodies in B cell malignancies.

Okroj M, Österborg A, Blom AM. Okroj M, et al. Cancer Treat Rev. 2013 Oct;39(6):632-9. doi: 10.1016/j.ctrv.2012.10.008. Epub 2012 Dec 5. Cancer Treat Rev. 2013. PMID: 23219151 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results